Share
Stacey Stevens
SimBioSys, a trailblazing TechBio company transforming cancer care through advanced AI and spatial biophysics has appointed Stacey Stevens as its new President and Chief Executive Officer.
With this strategic leadership addition, SimBioSys continues to advance its mission to revolutionize precision oncology. The company’s cutting-edge platform delivers deep insights into tumor biology, empowering clinicians to develop highly personalized treatment strategies that significantly improve patient outcomes.
By translating complex biological data into clinically actionable intelligence, SimBioSys is redefining how cancer is understood and treated.
Stevens brings over 20 years of executive leadership experience in healthcare and medical technology, with a strong focus on oncology innovation. As a founding partner at Ellevate, a global strategic advisory firm, she worked alongside both early-stage AI disruptors and Fortune 100 enterprises to accelerate the adoption of transformative breakthroughs in women’s health. Previously, as President and CEO of iCAD, she led the successful global commercialization of AI-powered breast cancer solutions and forged key partnerships, including with Google Health.
Earlier in her career, Stevens held senior commercial leadership roles at Philips Healthcare, Agilent Technologies, and Hewlett-Packard, driving growth across multiple imaging modalities.
Her appointment marks a significant milestone for SimBioSys as the company scales its impact in precision oncology and continues to deliver groundbreaking solutions at the intersection of technology and biology.
Related posts
